Randomized controlled trialHumanClinical Trial, Phase II

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial

Med (New York, N.Y.), 2026 May 8. Ji L, Jiang H, Cheng Z and 11 others.

Study type

Randomized controlled trial · Clinical Trial, Phase II

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Med (New York, N.Y.)

Published

2026 May 8

PubMed

PMID 41875890 ↗

DOI

10.1016/j.medj.2026.101063 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Mazdutide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

HumansFemaleMaleDouble-Blind MethodBody Mass IndexAdultObesityMiddle AgedWeight LossTreatment OutcomeChinaAnti-Obesity Agents

Other papers on Mazdutide

Systematic review / meta-analysis · 2026

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials

Randomized controlled trial · 2025

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Randomized controlled trial · 2023

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page